Page 13 - Pharma Intelligence News Today

Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence’s 2020 Pulse Report when the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they’d be more likely to take a COVID-19 vaccine if they had more information on the clinical trials has dropped by half since 2020 (14% from 28%). ...

Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence’s 2020 Pulse Report when the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they’d be more likely to take a COVID-19 vaccine if they had more information on the clinical trials has dropped by half since 2020 (14% from 28%). ...

Informa Business Intelligence: While Over Three-Quarters of Americans Are Willing to Take at Least One of the Authorized COVID-19 Vaccines, Nearly a Quarter Are Still Hesitant as the U.S. Changes Course on Mitigation Strategy Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligences 2020 Pulse Reportwhen the COVID-19 vaccines had yet to be made availa...

Deep Pharma Intelligence released a special 115-page analytical report Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts), which is

Author Bio Rachel primarily covers healthcare stocks for the Fool. She leverages her background and education in the legal field to inform her detailed research and analysis of the stock market. Its a remarkable time to be an investor. Over the past year, the market has not only recovered its losses from the coronavirus crash, but marked multiple days of new thrilling highs. The stock market has shown increased volatility in recent weeks. But for the time being, optimism...

Innoforce and dMed Collaborate to Accelerate the Development of Innovative Therapeutics News provided by Share this article Share this article HANGZHOU, China and SHANGHAI, March 2, 2021 /PRNewswire/ -- Innoforce, a biopharmaceutical innovation enabling platform and PDMO (Partner Development and Manufacturing Organization), and dMed, a clinical CRO with strong presence in China and the US - the worlds two largest pharmaceutical and drug development markets, have signed an agreement under whic...

4 feb 2021 Skipta Donates Critical Online Media Support to U.S. COVID-19 Vaccine Education Campaign Contribution will help the Ad Council and COVID Collaborative amplify their national education effort for healthcare professionals in the U.S. around COVID-19 vaccine safety and effectiveness NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Skipta, part of Informa Pharma Intelligence and the leading social network of specialized online medical communities for verified healthcare professionals (HCPs)...

Wednesday, 20 January 2021, 4:03 pm The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma giants Pfizer and Moderna are set for the lions share of 2021 vaccine sales. According to data presented by Finaria.it, BioNTech-Pfizer and Moderna COVID-19 vaccines sales are expected to generate $14.7bn in revenue by 2023. Moderna COVID-19 Vaccine Sales R...

Press Release – Psychic Ventures Ltd The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma giants Pfizer and Moderna are set for the …The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma gian...

Michael Duck takes on new global executive VP - commercial development role at Informa Markets.